Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.

Front Oncol · 2024 · PMC11133610 · PMID 38812776

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significancep=0.054so close (0.05 < p ≤ 0.1)

A decrease in fold-change in CXCL-11 demonstrated improved PFS but did not reach statistical significance (p=0.054).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.